A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734
Recruiting
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC characterized on the basis of epidermal growth factor receptor (EGFR) and Programmed-cell death Ligand (PD-L)1 status, in the Phase 2 (expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: City of Hope, Duarte, California +40 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
DETECT-RPC Universal EM Screening
NCT05958654
Recruiting
The purpose of this study is to evaluate whether the use of the Detection of Elder Mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool increases the average reporting of elder mistreatment (EM) by homebased primary care (HBPC) clinicians.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +6 locations
Conditions: Elder Abuse, Elder Mistreatment
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589
Recruiting
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
04/02/2025
Locations: Research Site, Montgomery, Alabama +123 locations
Conditions: Asthma
Register for Updates
Aveir AR Coverage With Evidence Development (CED) Study
NCT06100770
Recruiting
The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the single-chamber Aveir Atrial Leadless Pacemaker device (aka Aveir™ AR LP system).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Abbott, Sylmar, California
Conditions: Cardiac Pacemaker, Arrhythmia, Bradycardia
Register for Updates
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407
Recruiting
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must ha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Usc Norris Comprehensive Cancer Center, Los Angeles, California +50 locations
Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Register for Updates
Genomic Sequencing in Anatomically Normal Fetuses
NCT06211348
Recruiting
This cohort study will examine the clinical utility of genomic sequencing (GS) in patients undergoing prenatal diagnostic procedures (chorionic villus sampling or amniocentesis) for routine indications other than a structural fetal anomaly.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/02/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Pregnant Individuals Requesting Standard Microarray
Register for Updates
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
NCT06311578
Recruiting
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania +6 locations
Conditions: Advanced Solid Tumors
Register for Updates
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT06385080
Recruiting
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of California at San Diego Moores Cancer Center, La Jolla, California +46 locations
Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556
Recruiting
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Banner Health MD Anderson AZ, Gilbert, Arizona +239 locations
Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Register for Updates
THRIVE: Culturally AdapTed Harm Reduction Intervention
NCT06609278
Recruiting
The goal of this study is to develop and test a culturally adapted harm reduction intervention among Black adults who misuse opioids and stimulants. The questions it aims to answer include: will the culturally adapted harm reduction educational intervention increase overall knowledge of overdose and prevention/intervention techniques and increase confidence and willingness to use/teach interventions to others at-risk.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/02/2025
Locations: Louisville Central Community Center, Louisville, Kentucky +1 locations
Conditions: Opioid Use, Stimulant Use
Register for Updates
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148
Recruiting
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/02/2025
Locations: Retina Associates Southwest PC, Tucson, Arizona +37 locations
Conditions: Geographic Atrophy, Macular Degeneration
Register for Updates
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076
Recruiting
The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Providence Medical Foundation, Fullerton, California +51 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates